ethyl-(5,6,7,8-tetrahydro-[1]naphthyl)-amine | 140914-06-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: ethyl-(5,6,7,8-tetrahydro-[1]naphthyl)-amine
• 英文别名: 5-Aethylamino-tetralin；Aethyl-(5,6,7,8-tetrahydro-[1]naphthyl)-amin；Aethyl-tetralyl-(5)-amin；Aethyl-(ar.-tetrahydro-α-naphthylamin)；N-ethyl-5,6,7,8-tetrahydronaphthalen-1-amine
• CAS: 140914-06-3
• 化学式: C₁₂H₁₇N
• mdl: MFCD11142234
• 分子量: 175.274
• InChiKey: XCKCTTHTLKTLNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-氯-2-(2,6-二乙基苯基)-4-甲氧基-5,6,7,8-四氢喹啉 、 ethyl-(5,6,7,8-tetrahydro-[1]naphthyl)-amine 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 生成 2-(2,6-diethylphenyl)-N-ethyl-4-methoxy-N-(5,6,7,8-tetrahydronaphthalen-1-yl)-5,6,7,8-tetrahydroquinolin-5-amine
  参考文献：
  名称：

  Synthesis and characterization of 5,6,7,8-tetrahydroquinoline C5a receptor antagonists

  摘要：

  A novel series of substituted 2-aryl-5-amino-5,6,7,8-tetrahydroquinoline C5a receptor antagonists is reported. Synthetic routes were developed that allow the substituents on the tetrahydroquinoline core to be efficiently varied, facilitating determination of structure-activity relationships. Members of the series display high binding affinity for the C5a receptor and are potent functional antagonists. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.03.049
• 作为产物：
  描述：

  α-乙基氨基萘 在 戊醇 、 sodium 作用下， 生成 ethyl-(5,6,7,8-tetrahydro-[1]naphthyl)-amine
  参考文献：
  名称：

  Bamberger; Helwig, Chemische Berichte, 1889, vol. 22, p. 1315

  摘要：

  DOI：

文献信息

• BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Katayama Seiji

  公开号：US20130116227A1

  公开（公告）日：2013-05-09

  Disclosed is a novel biaryl amide derivative represented by formula (1) and having an affinity for the aldosterone receptor; also disclosed is a pharmaceutically acceptable salt thereof. (In the formula, A is any of the groups represented by formula (a); L is —CONH—, etc.; R 1 is a substitutable aminosulfonyl group, etc.; R 2 is a hydrogen atom, etc.; R 3 is a hydrogen atom, etc.; R 4 is a hydrogen atom, a halogen atom, hydroxy group, a substitutable amino group, a substitutable C 1-6 alkoxy group, a substitutable 4- to 7-membered cyclic amino group, etc.; R 5a , R 5b and R 5c are each independently hydrogen atoms, etc.; R 6 is a halogen atom, a cyano group, etc.; R 7 and R 8 are each independently a hydrogen atom, etc.; and m is an integer such as 0.)

  揭示了一种表示为公式（1）的新型联苯酰胺衍生物，具有与醛固酮受体的亲和力；还揭示了其药用可接受的盐。（在该公式中，A是由公式（a）表示的任何基团之一；L是—CONH—等；R1是可替代的氨基磺酰基等；R2是氢原子等；R3是氢原子等；R4是氢原子、卤原子、羟基、可替代的氨基基团、可替代的C1-6烷氧基、可替代的4-到7-成员环氨基基团等；R5a、R5b和R5c各自独立地是氢原子等；R6是卤原子、氰基等；R7和R8各自独立地是氢原子等；m是整数，例如0。）
• PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS
  申请人：Fink Brian E.

  公开号：US20090048244A1

  公开（公告）日：2009-02-19

  The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

  本发明提供公式I化合物及其药学上可接受的盐。公式I化合物抑制生长因子受体的酪氨酸激酶活性，如HER1、HER2和HER4，因此使它们有用作抗增殖剂。公式I化合物也适用于治疗与通过生长因子受体进行信号转导途径相关的其他疾病。
• DIPEPTIDE NITRILES
  申请人：Altmann Eva

  公开号：US20080027060A1

  公开（公告）日：2008-01-31

  N-terminal substituted dipeptide nitriles as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization). Particular dipeptide nitriles are compounds of formula I, or physiologically-acceptable and -cleavable esters or a salts thereof wherein: the symbols are as defined. In particular it has been found that by appropriate choice of groups R, R 2 , R 3 , R 4 , R 5 , X 1 , Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.

  N-末端取代二肽基腈可作为半胱氨酸蛋白酶的抑制剂，例如半胱氨酸蛋白酶B、K、L和S，并可用于治疗半胱氨酸蛋白酶依赖性疾病和病况，包括炎症、类风湿关节炎、骨关节炎、骨质疏松症、肿瘤（尤其是肿瘤侵袭和转移）、冠心病、动脉硬化（包括动脉粥样硬化斑块破裂和不稳定性）。特定的二肽基腈化合物为I式化合物，或其生理上可接受和可水解酯或其盐。其中：符号如定义。特别地，通过适当选择R、R2、R3、R4、R5、X1、Y和L基团，可以改变化合物作为各种半胱氨酸蛋白酶类型的抑制剂的相对选择性，例如获得选择性抑制特定半胱氨酸蛋白酶类型或半胱氨酸蛋白酶类型组合的抑制剂。
• DE338817
  申请人：——

  公开号：——

  公开（公告）日：——
• US7297695B2
  申请人：——

  公开号：US7297695B2

  公开（公告）日：2007-11-20